Assessment of platelet activation and phagocytic activity in gastric cancer patients

Table 1 Stage of gastric cancer n (%)

Group tested
Tumor stage	I+ II
(TNM classification)	6 (14)
	III
	18 (42)
	IV
	19 (44)
	T1
Depth of tumor invasion	2 (6)
	T2
	4 (13)
	T3
	15 (47)
	T4
	11 (34)
	N0
Lymph node metastases	7 (17)
	N1
	4 (9)
	N2
	13 (31)
	N3
	18 (43)
Distant metastases	M0
	9 (47)
	M1
	10 (53)

Table 2 Mean values of platelet counts, levels of soluble platelet-selectin and interleukin-6 in cancer patients-early carcinoma-E advanced carcinoma with lymph node involvement-A, metastatic cancer-M and in control group (mean ± SD)

	PLT	sP-selectin	IL-6
Study group E1	247.33 ± 42.92	67.93 ± 74.49	20.68 ± 6.31
	E1 vs C	E1 vs C	E1 vs C
	0.8 < P < 0.9	P < 0.05	P < 0.01
Study group E2	662.83 ± 335.23	153.37 ± 174.59	10.90 ± 8.43
	E1 vs E2	E1 vs E2	E1 vs E2
	P < 0.05	0.5 < P < 0.6	0.1 < P < 0.2
	E2 vs C	E2 vs C	E2 vs C
	P < 0.05	0.6 < P < 0.7	0.05 < P < 0.1
Study group A1	344.28 ± 266.40	193.23 ± 143.70	11.51 ± 8.44
	A1 vs C	A1 vs C	A1 vs C
	0.05 < P < 0.1	0.05 < P < 0.1	P < 0.001
Study group A2	584.25 ± 237.54	278.54 ± 158.64	20.42 ± 12.88
	A1 vs A2	A1 vs A2	A1 vs A2
	P < 0.05	P < 0.001	0.2 < P < 0.3
	A2 vs C	A2 vs C	A2 vs C
	P < 0.01	0.2 < P < 0.3	P < 0.05
Study group M1	335.84 ± 154.08	173.71 ± 116.79	8.44 ± 5.63
	M1 vs C	M1 vs C	M1 vs C
	P < 0.01	0.1 < P < 0.2	P < 0.001
Study group M2	451.55 ± 210.74	178.96 ± 84.56	15.26 ± 12.73
	M1 vs M2	M1 vs M2	M1 vs M2
	0.2 < P < 0.3	0.1 < P < 0.2	0.1 < P < 0.2
	M2 vs C	M2 vs C	M2 vs C
	P < 0.01	0.5 < P < 0.6	P < 0.05
Control group C	247.78 ± 44.74	130.38 ± 48.35	2.45 ± 1.44

PLT: Platelet count; sP-selectin: Soluble platelet selectin; IL: Interleukin.

Table 3 Assessment of phagocytic activity of blood platelets in gastric cancer patients-E, -A, -M and in control group (mean ± SD)

	Percentage of phag-ocytizing platelets	Phagocytic index
Study group early carcinoma E1	1.08 ± 0.08	1.02 ± 0.04
	E1 vs C	E1 vs C
	P < 0.001	P < 0.001
Study group early carcinoma E2	1.27 ± 0.10	1.07 ± 0.05
	E1 vs E2	E1 vs E2
	P < 0.05	0.05 < P < 0.1
	E2 vs C	E2 vs C
	P < 0.01	P < 0.01
Study group advanced carcinoma with lymph node involvement A1	1.10 ± 0.11	1.02 ± 0.11
	A1 vs C	A1 vs C
	P < 0.001	P < 0.001
Study group advanced carcinoma with lymph node involvement A2	1.23 ± 0.08	1.03 ± 0.06
	A1 vs A2	A1 vs A2
	P < 0.05	0.7 < P < 0.8
	A2 vs C	A2 vs C
	P < 0.001	P < 0.001
Study group metastatic cancer M1	1.13 ± 0.10	1.0 ± 0.07
	M1 vs C	M1 vs C
	P < 0.001	P < 0.001
Study group metastatic cancer M2	1.20 ± 0.12	1.05 ± 0.08
	M1 vs M2	M1 vs M2
	0.2 < P < 0.3	0.7 < P < 0.8
	M2 vs C	M2 vs C
	P < 0.001	P < 0.001
Control group C	2.26 ± 0.57	1.83 ± 0.37